Yeh Jennifer M, Hanmer Janel, Ward Zachary J, Leisenring Wendy M, Armstrong Gregory T, Hudson Melissa M, Stovall Marilyn, Robison Leslie L, Oeffinger Kevin C, Diller Lisa
Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA (JMY, ZJW); University of Pittsburgh Medical Center, Pittsburgh, PA (JH); Fred Hutchinson Cancer Research Center, Seattle, WA (WML); St. Jude Children's Research Hospital, Memphis, TN (GTA, MMH, LLR); University of Texas MD Anderson Cancer Center, Houston, TX (MS); Memorial Sloan Kettering Cancer Center, New York, NY (KCO); Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA (LD)
Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA (JMY, ZJW); University of Pittsburgh Medical Center, Pittsburgh, PA (JH); Fred Hutchinson Cancer Research Center, Seattle, WA (WML); St. Jude Children's Research Hospital, Memphis, TN (GTA, MMH, LLR); University of Texas MD Anderson Cancer Center, Houston, TX (MS); Memorial Sloan Kettering Cancer Center, New York, NY (KCO); Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA (LD).
J Natl Cancer Inst. 2016 Apr 21;108(9). doi: 10.1093/jnci/djw046. Print 2016 Sep.
Health utility, a summary measure of quality of life, has not been previously used to compare outcomes among childhood cancer survivors and individuals without a cancer history. We estimated health utility (0, death; 1, perfect health) using the Short Form-6D (SF-6D) in survivors (n = 7105) and siblings of survivors (n = 372) (using the Childhood Cancer Survivor Study cohort) and the general population (n = 12 803) (using the Medical Expenditures Panel Survey). Survivors had statistically significantly lower SF-6D scores than the general population (mean = 0.769, 95% confidence interval [CI] = 0.766 to 0.771, vs mean = 0.809, 95% CI = 0.806 to 0.813, respectively, ITALIC! P< .001, two-sided). Young adult survivors (age 18-29 years) reported scores comparable with general population estimates for people age 40 to 49 years. Among survivors, SF-6D scores were largely determined by number and severity of chronic conditions. No clinically meaningful differences were identified between siblings and the general population (mean = 0.793, 95% CI = 0.782 to 0.805, vs mean = 0.809, 95% CI = 0.806 to 0.813, respectively). This analysis illustrates the importance of chronic conditions on long-term survivor quality of life and provides encouraging results on sibling well-being. Preference-based utilities are informative tools for outcomes research in cancer survivors.
健康效用作为生活质量的一项综合指标,此前尚未被用于比较儿童癌症幸存者与无癌症病史个体的预后情况。我们使用简式36项健康调查量表的6维简表(SF-6D)对幸存者(n = 7105)及其同胞兄弟姐妹(n = 372)(使用儿童癌症幸存者研究队列)以及普通人群(n = 12803)(使用医疗支出小组调查)进行了健康效用评估(0代表死亡;1代表完全健康)。幸存者的SF-6D得分在统计学上显著低于普通人群(均值分别为0.769,95%置信区间[CI] = 0.766至0.771,以及均值为0.809,95% CI = 0.806至0.813,斜体!P <.001,双侧)。年轻成年幸存者(18 - 29岁)报告的得分与普通人群中40至49岁人群的估计得分相当。在幸存者中,SF-6D得分很大程度上由慢性病的数量和严重程度决定。未发现同胞兄弟姐妹与普通人群之间存在具有临床意义的差异(均值分别为0.793,95% CI = 0.782至0.805,以及均值为0.809,95% CI = 0.806至0.813)。该分析说明了慢性病对长期幸存者生活质量的重要性,并为同胞兄弟姐妹的健康状况提供了令人鼓舞的结果。基于偏好的效用是癌症幸存者预后研究的有用工具。